These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 6447532)

  • 1. Reduction in cholecystokinin-like immunoreactivity in the basal ganglia in Huntington's disease.
    Emson PC; Rehfeld JF; Langevin H; Rossor M
    Brain Res; 1980 Oct; 198(2):497-500. PubMed ID: 6447532
    [No Abstract]   [Full Text] [Related]  

  • 2. Cholecystokinin receptors are decreased in basal ganglia and cerebral cortex of Huntington's disease.
    Hays SE; Goodwin FK; Paul SM
    Brain Res; 1981 Nov; 225(2):452-6. PubMed ID: 6272931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholecystokinin content in the basal ganglia in Huntington's disease. The expression of cholecystokinin immunoreactivity in striatal grafts to ibotenic acid-lesioned rat striatum.
    Emson PC; Dawbarn D; Rossor MN; Rehfeld JF; Brundin P; Isacson O; Björklund A
    Ann N Y Acad Sci; 1985; 448():488-94. PubMed ID: 3161446
    [No Abstract]   [Full Text] [Related]  

  • 4. CCK receptors and human neurological disease.
    Hays SE; Paul SM
    Life Sci; 1982 Jul; 31(4):319-22. PubMed ID: 6292647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in basal ganglia and substantia nigra substance P levels in Huntington's disease.
    Buck SH; Burks TF; Brown MR; Yamamura HI
    Brain Res; 1981 Mar; 209(2):464-9. PubMed ID: 6164436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Peptides derived from prodynorphin are decreased in basal ganglia of Huntington's disease brains.
    Dawbarn D; Zamir N; Waters CM; Hunt SP; Emson PC; Brownstein MJ
    Brain Res; 1986 Apr; 372(1):155-8. PubMed ID: 2871898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease.
    De Souza EB; Whitehouse PJ; Folstein SE; Price DL; Vale WW
    Brain Res; 1987 Dec; 437(2):355-9. PubMed ID: 2893655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased TRH content of the basal ganglia in Huntington's disease.
    Spindel ER; Wurtman RJ; Bird ED
    N Engl J Med; 1980 Nov; 303(21):1235-6. PubMed ID: 6448349
    [No Abstract]   [Full Text] [Related]  

  • 9. Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease.
    Waeber C; Rigo M; Chinaglia G; Probst A; Palacios JM
    Synapse; 1991 Aug; 8(4):270-80. PubMed ID: 1656540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.
    Schülke JP; Brandon NJ
    Adv Neurobiol; 2017; 17():15-43. PubMed ID: 28956328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methionine-enkephalin and substance P in the basal ganglia of normals, Parkinson patients, Huntington patients, and schizophrenics. A qualitative immunohistochemical study.
    Zech M; Bogerts B
    Acta Neuropathol; 1985; 68(1):32-8. PubMed ID: 2413707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease.
    Dawbarn D; De Quidt ME; Emson PC
    Brain Res; 1985 Aug; 340(2):251-60. PubMed ID: 2862959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationships of aging changes in the basal ganglia to manifestations of Huntington's chorea.
    Finch CE
    Ann Neurol; 1980 May; 7(5):406-11. PubMed ID: 6446874
    [No Abstract]   [Full Text] [Related]  

  • 14. The distribution of GABAA-benzodiazepine receptors in the basal ganglia in Huntington's disease and in the quinolinic acid-lesioned rat.
    Faull RL; Waldvogel HJ; Nicholson LF; Synek BJ
    Prog Brain Res; 1993; 99():105-23. PubMed ID: 8108544
    [No Abstract]   [Full Text] [Related]  

  • 15. p75NTR in Huntington's disease: beyond the basal ganglia.
    Brito V; Ginés S
    Oncotarget; 2016 Jan; 7(1):1-2. PubMed ID: 26700963
    [No Abstract]   [Full Text] [Related]  

  • 16. Neurochemical substrates of rigidity and chorea in Huntington's disease.
    Storey E; Beal MF
    Brain; 1993 Oct; 116 ( Pt 5)():1201-22. PubMed ID: 7693298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopa as an antimetabolite in Huntington's disease.
    Baskin F; Rosenberg RN
    Lancet; 1973 Mar; 1(7803):582-3. PubMed ID: 4120646
    [No Abstract]   [Full Text] [Related]  

  • 18. Somatostatin is increased in the nucleus accumbens in Huntington's disease.
    Beal MF; Bird ED; Langlais PJ; Martin JB
    Neurology; 1984 May; 34(5):663-6. PubMed ID: 6143284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Huntington's disease: regional alteration in muscarinic cholinergic receptor binding in human brain.
    Wastek GJ; Stern LZ; Johnson PC; Yamamura HI
    Life Sci; 1976 Oct; 19(7):1033-9. PubMed ID: 136582
    [No Abstract]   [Full Text] [Related]  

  • 20. Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain.
    Perry TL; Hansen S; Kloster M
    N Engl J Med; 1973 Feb; 288(7):337-42. PubMed ID: 4345566
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.